Get started
Author

Yann Bergé

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors
2011 · Luis G. Paz-Ares, Carlos Gomez-Roca, et al. · Journal of Clinical Oncology · 80
A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
2013 · P A Cassier, A Lefranc, et al. · British Journal of Cancer · 71
PDF
Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors
2011 · Pierre Zindy, Yann Bergé, et al. · Cancer Research · 62
A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies
2015 · A Spreafico, J-P Delord, et al. · British Journal of Cancer · 37
PDF
RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor
2013 · Claire Médale-Giamarchi, Isabelle Lajoie-Mazenc, et al. · Breast Cancer Research · 35
PDF
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
2013 · Jean-Pierre Delord, Josep Tabernero, et al. · European Journal of Cancer · 25
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
2020 · Yves Rinaldi, Anne-Laure Pointet, et al. · European Journal of Cancer · 21
Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study
2019 · E. Pons-Tostivint, L. Daubisse-Marliac, et al. · The Breast · 20
Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.
2011 · A. Blesius, P. A. Cassier, et al. · Journal of Clinical Oncology · 16
Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival.
2011 · A. Cioffi, A. Italiano, et al. · Journal of Clinical Oncology · 15
Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors.
2011 · R. Bahleda, J. Soria, et al. · Journal of Clinical Oncology · 12
Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
2018 · Rastislav Bahleda, Andrea Varga, et al. · British Journal of Cancer · 10
PDF
A phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors.
2012 · Nicolas Isambert, Antoine Hollebecque, et al. · Journal of Clinical Oncology · 6
Phase I trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumors.
2012 · Antoine Hollebecque, Rastislav Bahleda, et al. · Journal of Clinical Oncology · 6
Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.
2013 · Leticia De Mattos-Arruda, Lillian L. Siu, et al. · Journal of Clinical Oncology · 4
374 Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) results of first-in-man phase I trial of the orally available MEK-inhibitor MSC1936369 (AS703026) in patients (pts) with advanced solid tumors
2010 · A. Awada, N. Houedé, et al. · European Journal of Cancer Supplements · 2
Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant metastatic colorectal carcinoma (mCRC) patients treated with RG7160 (GA201), an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal anti-EGFR antibody.
2013 · Jean-Pierre Delord, Josep Tabernero, et al. · Journal of Clinical Oncology · 1
Efficacy and safety of panobinostat (LBH-589), a histone-deacetylase inhibitor (HDACi), in patients (pts) with advanced, previously treated soft tissue sarcoma (STS) and sex cord tumors (SCT): A study from the French Sarcoma Group.
2012 · Philippe Alexandre Cassier, Anne Lefranc, et al. · Journal of Clinical Oncology · 1
Pivotal role for typing of renal infiltrates: kidney localisation of a lymphoma presenting as pembrolizumab-associated nephritis. A lesson for the clinical nephrologist
2025 · Rayane Benyahia, Olivier Roques, et al. · Journal of Nephrology
PDF
Supplementary Tables 1-2, Figures 1-2, Material and Methods from Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors
2023 · Pierre Zindy, Yann Bergé, et al.
PDF
Data from Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors
2023 · Pierre Zindy, Yann Bergé, et al.
Exploratory pharmacodynamics (PD) trial to investigate the mechanism of action of RG7160 (GA201), a novel dual-acting, monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), compared with cetuximab (C) in neoadjuvant head and neck squamous cell carcinoma (HNSCC).
2012 · Stéphane Temam, James F. Spicer, et al. · Journal of Clinical Oncology
Comment augmenter la performance des médicaments anti-HER?
2012 · F. Dalenc, Y. Bergé, et al. · Springer eBooks
Correlation between RhoB and Estrogen Receptor α (ERα) Expressions: From Experimental Data to Human Breast Tumors.
2009 · F. Dalenc, T. Filleron, et al. · Cancer Research
Influence of EIF4E and HER2 Protein Expression on the Response to Neoadjuvant Chemotherapy and Trastuzumab in Breast Cancer.
2009 · Y. Bergé, T. Filleron, et al. · Cancer Research
Works count: 28
Citation count: 424
H-index: 11
I10-index: 12
Year
Topic
Type